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 ABSTRACT 
Staphylococcus aureus is a leading cause of intrama-
mmary infections (IMI). We recently demonstrated 
that Staph. aureus strains express the gene guaA
during bovine IMI. This gene codes for a guanosine 
monophosphate synthetase and its expression is regu-
lated by a guanine riboswitch. The guanine analog 
2,5,6-triaminopyrimidine-4-one (PC1) is a ligand of the 
guanine riboswitch. Interactions between PC1 and its 
target result in inhibition of guanosine monophosphate 
synthesis and subsequent death of the bacterium. The 
present study describes the investigational use of PC1 
for therapy of Staph. aureus IMI in lactating cows. The 
in vitro minimal inhibitory concentration of PC1 ranged 
from 0.5 to 4 μg/mL for a variety of Staph. aureus
and Staphylococcus epidermidis strains and required a 
reducing agent for stability and full potency. A safety 
assessment study was performed, whereby the healthy 
quarters of 4 cows were infused with increasing doses of 
PC1 (0, 150, 250, and 500 mg). Over the 44 h following 
infusions, no obvious adverse effect was observed. Ten 
Holstein multiparous cows in mid lactation were then 
experimentally infused into 3 of the quarters with ap-
proximately 50 cfu of Staph. aureus strain SHY97-3906 
and infection was allowed to progress for 2 wk before 
starting PC1 treatment. Bacterial counts reached then 
about 103 to 104 cfu/mL of milk. Infected quarters were 
treated with 1 of 3 doses of PC1 (0, 250, or 500 mg) 
after each morning and evening milking for 7 d (i.e., 
14 intramammary infusions of PC1). During the treat-
ment period, milk from PC1-treated quarters showed a 
significant reduction in bacterial concentrations. How-
ever, this reduction of Staph. aureus count in milk was 
not maintained during the 4 wk following the end of the 
treatment and only 15% of the PC1-treated quarters 
underwent bacteriological cure. The somatic cell count 
and the quarter milk production were not affected 
by treatments. Although bacterial clearance was not 
achieved following treatment with PC1, these results 
demonstrate that the Staph. aureus guanine riboswitch 
represents a relevant and promising drug target for a 
novel class of antibiotics for the animal food industry. 
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 INTRODUCTION 
 Bovine mastitis is an inflammation of the udder that 
results from infection or trauma, and represents a fre-
quent and costly disease for dairy producers (Seegers et 
al., 2003). Intramammary infection is often caused by 
the contagious bacterium Staphylococcus aureus that is 
highly transmittable, especially during milking (Sears 
and McCarthy, 2003; Olde Riekerink et al., 2008). 
Staphylococcal IMI exemplify difficult-to-treat persis-
tent infections and relapses can lead to a chronic mas-
titis disease. Antibiotic treatment of IMI is problematic 
partly because in vitro antibacterial susceptibility is a 
poor predictor of efficacy in chronically infected cows 
(Owens et al., 1997). Cure rates for Staph. aureus mas-
titis rarely achieve 50% with currently available thera-
pies (Radostits and Done, 2007). Although reinfections 
that follow attempts to treat acute mastitis can be due 
to newly acquired strains, they are often the result 
of the persistence of the original infective organism 
(Barkema et al., 2006). Current therapy thus often fails 
to eradicate the infection. As a result, novel approaches 
to treat staphylococcal IMI are urgently needed (Oliver 
et al., 2011). 
 The mammalian host environment can modulate 
gene expression of bacteria, including that of Staph. 
aureus (Lowe et al., 1998; Allard et al., 2006). In vivo 
expression suggests the importance of a gene for bac-
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terial survival in the host and the analysis of Staph. 
aureus gene expression during infection should help to 
identify elements which may be useful as drug targets. 
As part of our efforts to discover new antibiotherapies, 
we recently reported that the Staph. aureus gene guaA 
is expressed during bovine mastitis and we documented 
its expression mechanism (Mulhbacher et al., 2010; Al-
lard et al., 2012). In staphylococci, guaA is coding for a 
guanosine monophosphate (GMP) synthetase and this 
gene expression is under the control of a guanine ribo-
switch. In the absence of guanine, the structure of the 
guanine riboswitch folds into the “on” state, which al-
lows transcription of the entire mRNA molecule and the 
subsequent expression of encoded proteins that include 
the GMP synthetase. In contrast, upon guanine bind-
ing to the aptamer domain (i.e., core of the riboswitch 
structure that accommodates the ligand), the ribo-
switch folds into the “off” state, forming a transcription 
terminator that prevents gene expression and GMP 
synthesis. Interestingly, we recently demonstrated that 
the guanine riboswitch can be targeted by a drug-like 
small-molecule ligand named 2,5,6-triaminopyrimidine-
4-one (PC1), which mimics guanine and can block gene 
expression and essential GMP synthesis (Mulhbacher et 
al., 2010). Noteworthy, both the function of guaA and 
its regulation seem essential for bacteria. Furthermore, 
we have previously demonstrated that in vitro, there 
is no development of resistance to PC1 in Staph. au-
reus after 30 passages in the presence of subminimal 
inhibitory concentrations of the drug, suggesting that 
mutations leading to a constitutive expression of guaA 
may not readily occur (Mulhbacher et al., 2010). It is, 
thus, possible that maintaining a functional riboswitch 
to control guaA expression is a vital process that bac-
teria cannot bypass, making guaA and its riboswitch 
potential new targets for chemotherapy. We also previ-
ously demonstrated that PC1 was able to significantly 
reduce Staph. aureus infection in a murine model of IMI 
(Mulhbacher et al., 2010). In this article, we evaluated 
the efficacy of PC1 for treatment of bovine mastitis to 
further validate the importance of the Staph. aureus 
guanine riboswitch as a novel drug target.
MATERIALS AND METHODS
All animal experiments were approved by the Ag-
riculture and Agri-Food Canada local institutional 
animal care committee (Sherbrooke, QC, Canada) and 
conducted in accordance with the guidelines of the Ca-
nadian Council on Animal Care (Ottawa, ON, Canada).
Bacterial Strains
The Staph. aureus strain SHY97-3906, which was 
originally isolated from a clinical case of bovine mas-
titis during lactation (Diarra et al., 2002), was used 
for experimental bovine IMI. Multilocus sequence typ-
ing was performed using the procedure previously de-
scribed (Enright et al., 2000). Multilocus sequence typ-
ing analysis revealed that the sequence type of strain 
SHY97-3906 was ST151 (i.e., the same as the common 
bovine mastitis strain ET3 (RF122), a virulent clonal 
subtype known to cause important tissue damage and 
mortality in experimental mastitis in the mouse (Gui-
nane et al., 2008). Strain SHY97-3906 was previously 
used in other projects related to the riboswitch inhibi-
tor and to bacterial gene expression studies (Allard et 
al., 2006, 2012; Mulhbacher et al., 2010). Staphylococ-
cus aureus Newbould (ATCC 29740), ATCC 29213 and 
Staphylococcus epidermidis ATCC1228 were used for 
antimicrobial agent susceptibility testing. Additional 
bovine mastitis strains were also included in antimi-
crobial agents susceptibility testing. Briefly, strains no. 
3, 557, and 1290 were originally isolated from cows at 
the end of lactation with mastitis that persisted for at 
least 55 d between dry-off and calving. Strain no. 3 had 
the ST352 that is the same found in multiple bovine 
isolates causing subclinical mastitis (Smyth et al., 2009; 
Hata et al., 2010).
Susceptibility of Staph. aureus and Staph. 
epidermidis to Antimicrobial Agents
The MIC of PC1 (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA) and classical antibiotics were deter-
mined by a broth microdilution technique following the 
recommendations of the Clinical Laboratory Standard 
Institute (CLSI, 2011). Oxacillin, vancomycin, erythro-
mycin, gentamicin, cephapirin, and enrofloxacin were 
all from Sigma-Aldrich (Oakville, ON, Canada) and 
pirlimycin hydrochloride was from Pfizer Animal Health 
(Kirkland, QC, Canada). The cation-adjusted Muller 
Hinton broth (CAMHB; Becton Dickinson Canada 
Inc., Mississauga, ON, Canada) used for susceptibil-
ity tests was supplemented with 1.5 mM dithiothreitol 
(DTT; Sigma-Aldrich) to protect PC1 from oxidative 
self-condensation (i.e., a dimerization associated with a 
change in color; Taylor et al., 1955) during compound 
preparation and in vitro tests.
Initial Safety Assessment for PC1
A preliminary safety assessment of PC1 was conduct-
ed to confirm the absence of a negative reaction to the 
doses to be used in the clinical trial. Four healthy cows 
in mid lactation and exempt of IMI in their 4 quarters 
were infused with 1 of 4 doses of PC1 (0, 150, 250, or 
500 mg in saline) in each quarter after the morning 
milking. Cows were monitored for 44 h at each of 4 
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milkings for body temperature and udder redness and 
swelling. Individual quarter milk was also collected at 
each milking (n = 4 for each PC1 dose) to measure 
milk production and to allow sample harvesting for 
determination of SCC (n = 4 for each PC1 dose) and 
determination of the acute-phase protein milk amyloid 
A (MAA). For MAA, 1 additional sampling was done 
6 h after the infusion of PC1 (n = 5 for each PC1 dose). 
Milk amyloid A dosage was performed with the MAA 
assay kit from Tridelta Development Ltd. (Maynooth, 
Ireland) according to their recommendations. The SCC 
was determined in a commercial laboratory (Valacta 
Inc., Sainte-Anne-de-Bellevue, QC, Canada).
Experimental IMI
Before the animal trial, the relation between the 
absorbance of bacterial cultures (absorbance at a wave-
length of 600 nm, A600nm) and colony-forming units 
was determined. The day of the challenge, a volume 
of the overnight culture of Staph. aureus in Mueller 
Hinton broth (MHB; Becton Dickinson Canada Inc.) 
was transferred to 200 mL of fresh MHB to obtain an 
A600nm of 0.1 and grown at 35°C until the A600nm reached 
a value corresponding to 108 cfu/mL in the exponential 
phase of growth. For intramammary infusions, bacteria 
were then diluted in sterile physiological saline (Baxter 
Healthcare Corp., Deerfield, IL) to obtain approxi-
mately 50 cfu in 3 mL. The plating of the inoculum 
on TSA confirmed that it actually contained 59 cfu in 
3 mL.
Ten healthy multiparous Holstein cows in mid lac-
tation were housed at the Dairy and Swine Research 
and Development Centre of Agriculture and Agri-Food 
Canada (Sherbrooke, QC, Canada). Prior to experi-
mental infection, SCC determinations and bacterial 
analysis of aseptic quarter milk samples were done to 
ensure that selected cows were free of IMI. After al-
lowing cows to adapt to the barn (1 wk), experimental 
infusion of mammary quarters with bacteria was ran-
domly performed in 3 of the 4 quarters of each cow 
after the evening milking according to a procedure 
previously described (Petitclerc et al., 2007) with few 
modifications. Briefly, before inoculation, teats were 
scrubbed with gauzes soaked in 70% ethanol. Teats 
were allowed to air dry and intramammary infusion of 
a bacterial suspension (3 mL containing 59 cfu) was 
performed into 3 of the 4 quarters. Immediately after 
infusion, all quarters were thoroughly massaged and 
teats were dipped in an iodophor-based teat sanitizer. 
Disposable gloves were worn throughout the procedure 
and disinfected before proceeding to the next animal. 
All quarters infused with Staph. aureus became infected 
and all cows showed clinical signs of mastitis the first 
few days after intramammary infusion of Staph. aureus 
(inflammation or poor milk appearance, or both). For 
animal welfare, when body temperature exceeded 40°C 
and persisted over a 24-h period, a nonsteroidal antiin-
flammatory drug was injected (Flunazine; Vétoquinol 
Canada Inc., Lavaltrie, QC, Canada; 1 mL/45 kg of 
BW). During this study, 4 cows received 1 injection and 
2 cows received 3 injections before the treatment period 
(infection period) and 1 cow received 1 injection and 1 
cow received 3 injections during the treatment period. 
No impact was expected on any specific experimental 
treatment, as each cow received all of the treatments 
(see below).
Milk Sample Collection
Milk was collected using individual quarter milking 
units at morning milking and weighed for the determi-
nation of quarter milk production. Samples were taken 
3 times per week except during the treatment period 
where samples were taken daily. Between milking of 
each cow, the milking units were thoroughly washed 
and disinfected with an iodine-based germicide deter-
gent (K.O. Dyne; GEA Farm Technologies, Westmo-
reland, NY). All other materials in contact with milk 
were disinfected with 70% ethanol. After foremilk was 
discarded, a 10-mL aseptic milk sample was collected 
for each individual quarter in a 50-mL sterile vial. Milk 
samples were serially diluted and 100 μL were plated 
on both tryptic soy agar (Becton Dickinson Canada 
Inc.) and mannitol salt agar plates (Becton Dickin-
son Canada Inc.) for Staph. aureus identification and 
colony-forming unit determinations. Plates were then 
incubated 24 h at 35°C before colony counting. The 
dilutions that showed between 30 and 300 colonies were 
considered for calculation of the bacterial concentra-
tion. Each dilution was plated in duplicate. A nonas-
eptic 50-mL sample was also taken from each quarter 
at milking for the determination of SCC (Valacta Inc.).
Evaluation of PC1 Efficacy for Treatment  
of Experimental Staph. aureus IMI
Experimental IMI were allowed to progress for 2 
wk for bacterial counts to stabilize (usually reach-
ing approximately 103 to 104 cfu/mL of milk) before 
treatment initiation. Intramammary treatments were 
initiated after morning milking and repeated twice per 
day after each milking for 7 consecutive days (a total 
of 14 intramammary infusions of PC1; i.e., starting 
after the morning milking at d 1 and finishing at the 
evening milking at d 7). Within each cow, a quarter 
was randomly treated with saline (50 mL), whereas 
2 others randomly received 1 of 2 doses of PC1 (250 
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mg or 500 mg in 50 mL). The saline and PC1 doses 
were prepared with 1.5 mM DTT to limit the oxidation 
self-condensation of PC1 before its infusion into the 
mammary glands. Aseptic and nonaseptic milk samples 
were taken every day at morning milking during the 
treatment period and once per week for 4 wk after the 
end of treatment (monitoring period) for the determi-
nation of viable bacterial concentrations and SCC as 
described above.
Statistical Analysis
Statistical analyses of the data were performed us-
ing the PROC MIXED of SAS (SAS Institute Inc., 
Cary, NC) as repeated measurements. The subject was 
treatment (cow) and cow was included as a fixed ef-
fect in the model. For the PC1 safety assessment, data 
contrasts were used to compare the 3 doses of PC1 
with the saline treatment. For the experimental PC1 
therapy, orthogonal contrasts were used to compare 
control quarters with those that received either dose 
of PC1 and to compare the 2 doses of PC1. The Tukey 
adjusted test was used for other treatment compari-
sons. The data from the pretreatment, treatment, and 
posttreatment (monitoring) periods were analyzed 
separately. Pretreatment data (colony-forming units, 
milk production, and SCC) were used as covariables for 
the analysis of data of the treatment and monitoring 
periods. For the analysis of SCC and bacterial counts, 
data were log10 transformed before analysis.
RESULTS
Antimicrobial Agent Activity
The MIC of PC1 ranged from 0.5 to 4 μg/mL for a 
variety of Staph. aureus and Staph. epidermidis (Table 
1). As the oxidative self-condensation of PC1 (Taylor 
et al., 1955) could impair its in vitro activity, the in 
vitro activity of PC1 was evaluated in the presence 
of a reducing agent (DTT). The lowest concentration 
of DTT that provided PC1 its maximal antibacterial 
activity was 1.5 mM, whereas the MIC of DTT itself 
was >75 mM. Using a freshly made PC1 solution, the 
MIC of PC1 against Staph. aureus ATCC 29213 was 
established at 2 μg/mL and 64 to 128 μg/mL with or 
without DTT, respectively. For all the strains tested, 
the MIC of PC1 was greatly improved by the presence 
of DTT, whereas DTT had no effect on the MIC of the 
other antimicrobial agents tested (data not shown).
Safety Assessment Study
In a preliminary safety assessment study, 3 doses of 
PC1 and saline (0, 150, 250, and 500 mg) were directly 
infused in the 4 quarters of 4 healthy cows immediately 
after morning milking as done with other commercially 
available drugs for the treatment of bovine mastitis. 
The SCC, quarter milk production, and concentration 
of the acute-phase protein MAA were not affected by 
treatments during the 44 h following infusion of PC1 
(Table 2). Intramammary infusion of PC1 also did not 
affect the body temperature, which was maintained 
around 38°C for each cow. Neither redness nor swelling 
was observed at the milkings for any of the quarters. 
Because no obvious side effect was observed with the 
infusion of PC1 into the mammary glands of mice (Mul-
hbacher et al., 2010) or dairy cows during this safety 
assessment assay, we judged PC1 to be safe to be used 
for the rest of the study.
Evaluation of PC1 for the Treatment of IMI
2,5,6-Triaminopyrimidine-4-one was then used for 
the treatment of 10 experimentally infected cows. The 
30 infected quarters (3 per cow) were infused after ev-
Table 1. The MIC of 2,5,6-triaminopyrimidine-4-one (PC1) and classical antibiotics against 2 staphylococcal species 
Strain
MIC1 (μg/mL)
PC12
OXA VAN ERY GEN CEP PIR ENR−DTT +DTT
Staphylococcus aureus
 ATCC 29213 64–128 2 0.12–0.25 1 0.5 0.25–0.5 0.25 0.25 0.12–0.25
 Newbould 128 1–2 0.12 1 0.25 0.25 0.12 0.25 0.06–0.12
 SHY97-3906 64–128 2 0.25 1 0.25 0.12 0.12 0.12 0.12
 3 64–128 0.5–2 0.12 1 0.25 0.25 0.12–0.25 0.25 0.12–0.25
 557 64–128 1–2 0.12 1–2 0.25 0.25–0.5 0.06–0.12 0.25 0.06
 1290 64–128 1 0.12–0.25 2 0.25–0.5 0.25 0.12 0.25 0.12
Staphylococcus epidermidis  
 ATCC 12228 64 2–4 0.06–0.12 2 0.12–0.25 0.06 0.12 0.06–0.12 0.12
1Antibiotic MIC were determined in cation-adjusted Muller Hinton broth (CAMHB; Becton Dickinson Canada Inc., Mississauga, ON, Canada). 
The MIC of oxacillin (OXA), vancomycin (VAN), erythromycin (ERY), gentamicin (GEN), cephapirin (CEP), pirlimycin (PIR), and enrofloxa-
cin (ENR) were not modified in the absence or presence of 1.5 mM dithiothreitol (DTT; data not shown).
2The MIC of PC1 was reduced by the presence of 1.5 mM DTT. The MIC of DTT is >75 mM.
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ery milking during 7 d with either 250 or 500 mg of 
PC1 or saline (all prepared in 1.5 mM DTT). During 
the treatment period, the number of viable bacteria 
was significantly lower in the quarters that received 
PC1 compared with those that received saline (Figure 
1; P = 0.02). No difference was observed between the 
2 doses of PC1, which similarly affected the bacterial 
count (P = 0.48). After the treatment period (monitor-
ing period), the bacterial count in PC1-treated quarters 
increased and was no longer statistically different from 
that of control quarters (Figure 1A). The cure rate, de-
fined as no detectable bacteria (cfu) for 2 milk samples 
taken 2 wk apart, with the first sample taken 1 wk after 
the end of the treatment, was 15% for the PC1-treated 
quarters versus 0% for the quarters that received saline 
(P = 0.2). No significant difference was observed in 
quarter milk production or SCC over the treatment and 
monitoring periods (Table 3).
DISCUSSION
The Staph. aureus strain SHY97-3906 was used in 
this study to evaluate the efficacy of PC1 for the treat-
ment of bovine IMI. We chose this strain because it 
originated from a typical clinical mastitis case and for 
its sequence type (ST151), which is representative of 
many mastitis isolates. Also, we showed that this strain 
was as susceptible as others to PC1 in vitro and that 
gene guaA (under the control of the guanine riboswitch 
target of PC1) was strongly expressed during bovine 
mastitis similarly to that found for 3 other mastitis 
isolates (Allard et al., 2012).
All staphylococci strains tested were affected by 
the antibiotic activity of PC1, showing MIC ranging 
from 0.5 to 4 μg/mL (Table 1). In our previous report 
(Mulhbacher et al., 2010), because of the high level of 
efficacy of PC1 in a mouse mastitis model of infection, 
we soon realized that the oxidative self-condensation 
of PC1 (Taylor et al., 1955) might have impaired its 
in vitro activity. Inversely, it seemed that the micro-
aerobic environment (i.e., low oxidative environment) 
of the mastitic milk (Mayer et al., 1988) might have 
improved its activity in the mouse (Mulhbacher et al., 
2010). Indeed, the addition of 1.5 mM DTT to the 
PC1 preparation greatly improved its in vitro MIC 
by protecting PC1 against oxidation (Table 1). In the 
presence of 1.5 mM DTT, the MIC of PC1 gets closer 
to the MIC of antibiotics (cephapirin, pirlimycin, and 
enrofloxacin) commonly used for the treatment of bo-
vine mastitis. Interestingly, PC1 is also effective against 
Staph. epidermidis (MIC of 2 to 4 μg/mL), which is one 
of the CNS frequently causing IMI. Indeed, although 
Staph. aureus is one of the most prevalent bacterial 
species recovered from mastitis cases occurring during 
lactation in Canadian farms, the CNS are also often 
involved in bovine mastitis and have drawn more and 
more attention in recent years (Thorberg et al., 2009; 
Reyher et al., 2011). In addition, we have previously 
shown the in vitro activity of PC1 against a methicillin-
resistant Staph. aureus strain isolated from a human 
(Mulhbacher et al., 2010), despite its multi-resistance 
to traditional drugs (β-lactams, ciprofloxacin, erythro-
mycin, gentamicin, and tetracycline). A new treatment 
mechanism such as that represented by PC1 is, there-
fore, most certainly of interest considering the recent 
emergence of bovine methicillin-resistant Staph. aureus, 
which have been shown to be transmittable to humans 
(García-Álvarez et al., 2011; Haran et al., 2012).
Our preliminary safety assessment for the use of PC1 
in cows yielded no obvious adverse effect. In addition, 
PC1 is well tolerated in rodents (Scientific Committee 
on Consumer Products of the European Commission, 
2008). In short, the NOAEL (no observed adverse ef-
fect level, in repeated doses administered in rats by ga-
Table 2. Effect of 1 intramammary infusion of saline or 2,5,6-triaminopyrimidine-4-one (PC1) at the indicated 
dose to healthy cows on SCC, acute-phase protein milk amyloid A (MAA), and quarter milk production over 
a 44-h period 
Infusion1
SCC  
(log10/mL of milk; n = 4)
2,3
Quarter milk  
production  
(kg; n = 5)2,3
MAA  
(ng/mL; n = 5)2,3
Saline 4.94 ± 0.12 3.09 ± 0.40 225.75 ± 25.75
PC1
 100 mg 5.29 ± 0.10 2.24 ± 0.21 290.43 ± 34.90
 250 mg 5.21 ± 0.13 2.57 ± 0.15 263.23 ± 35.92
 500 mg 5.18 ± 0.10 3.34 ± 0.37 255.65 ± 39.87
1Saline and the different doses of PC1 were randomly infused in the 4 quarters of 4 healthy dairy cows.
2Data presented are LSM ± SEM. No statistical difference was observed for these parameters.
3After infusion of PC1 or saline, cows were monitored during 44 h at each of 4 milkings. Individual quarter 
milk was collected at each milking (n = 4 for each PC1 dose) to measure milk production and to allow sample 
collection for determination of SCC (n = 4 for each PC1 dose) and determination of MAA. For MAA, 1 ad-
ditional sampling was done 6 h after the infusion of PC1 (n = 5 for each PC1 dose).
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Figure 1. Experimental treatment of Staphylococcus aureus bovine IMI with 2,5,6-triaminopyrimidine-4-one (PC1). Ten Holstein multiparous 
cows in mid lactation were experimentally infused in 3 quarters with 59 cfu of Staph. aureus strain SHY97-3906 and infection was allowed to 
progress for 2 wk before starting PC1 treatment at d 1 (pretreatment period). Each of the 10 cows was then treated with PC1 (250 or 500 mg) 
or saline for 7 d in 3 infected mammary quarters, respectively. Each of those treatments was infused twice daily (a total of 14 intramammary 
infusions of PC1) starting after the morning milking at d 1 and finishing at the evening milking at d 7 (treatment period). (A) Kinetics of the 
bacterial concentrations in milk (log10 cfu/mL) for each group during the pretreatment, treatment, and monitoring periods. Each dot represents 
the LSM ± SEM of the bacterial concentrations in milk obtained for 10 quarters (10 cows). (B) Distribution of the bacterial concentrations in 
milk during the entire treatment period shown in A. Each dot represents the average bacterial count (cfu/mL) for each day of the 7-d treatment 
period for each group. Horizontal bars represent the LSM of bacterial counts over the treatment period for the different groups and vertical bars 
are the SEM. Orthogonal contrasts indicated that PC1 significantly reduced the bacterial count (cfu/mL) milk but that no difference existed 
between the 2 doses of PC1 during the treatment period.
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vage) was determined to be 200 mg/kg of BW per day 
(once daily, 28 d, 7 d per week). Of note, PC1 is also a 
nonribosylable analog that differentiates its molecular 
structure from canonical purines (such as guanine) or 
pyrimidines, thus preventing incorporation into nucleic 
acids and off-target effects (Mulhbacher et al., 2010). 
These data further support the potential success of the 
new drug class and will provide guidelines for future 
compounds of the PC1 (pyrimidine) scaffolds.
The present study is the first report on the use of 
PC1 for experimental therapy of bovine IMI. Although 
only 15% of the PC1-treated quarters were cured (vs. 
0% for the untreated controls, P = 0.2), intramammary 
infusions of PC1 significantly reduced the viable counts 
of Staph. aureus during bovine IMI (Figure 1). The PC1 
dose of 250 mg reduced the milk bacterial load of 1.23 
log10, on average, during the treatment period (Figure 
1B). Interestingly, the 500-mg dose of PC1 was not 
more efficient than the 250-mg dose and correlated with 
the observation that the 500-mg dose displayed more 
oxidative self-condensation of PC1 (i.e., a dimerization 
associated with a change in color) during preparation 
of the high-dose solution in the laboratory, despite the 
presence of 1.5 mM DTT. Although stability, dosage, 
and formulation of the drug will need to be improved in 
future studies, our results demonstrate that the inter-
ruption of Staph. aureus guaA expression by PC1 can 
translate in a significant antibacterial activity in cows. 
2,5,6-Triaminopyrimidine-4-one is the first member of 
this new class of antibiotics. Before pursuing the de-
velopment of this new drug class, it was necessary to 
show a proof of concept in cows. At this time, it is 
difficult to know if an approximately 1 log10 decrease in 
bacterial count would represent a useful outcome in the 
field but it supports the idea that new molecules can 
be designed to improve the efficacy of PC1. Also, our 
experimental model represents quite a challenge [i.e., 
an infusion of bacteria through the teat sphincter and 
directly up into the cistern, thus also bypassing the 
keratin layer (natural defense) of the teat canal]. The 
fact that all infused mammary quarters of all 10 cows 
rapidly developed clinical mastitis upon bacterial infu-
sion corroborates the robustness of the challenge and 
it is possible that naturally infected cows would better 
respond to treatment. Now that the proof of concept is 
done, future experiments should include new analogs of 
PC1 and a known commercial antibiotic as a control 
to put in context the relative difficulty in achieving 
bacteriological cures in this experimental model. Future 
experiments should also demonstrate in vivo efficacy 
against a variety of Staph. aureus strains.
The US Food and Drug Administration issued draft 
guidance intended to help reduce the development of 
resistance to medically important antimicrobial drugs 
used in food-producing animals (US FDA, 2010). 
Hence, an increasing demand exists to come up with 
new antibiotic products that can specifically be used in 
the animal food industry. The development of a novel 
drug class that tackles specific pathogens such as Staph. 
aureus in the agri-food sector would be most welcome. 
Indeed, PC1 is one of the rare new classes of antibac-
terial molecules (novel scaffold and mode of action) 
discovered since 1968. In fact, only the oxazolidinones 
(approved in 2000) fit in this category (Powers, 2004). 
Preliminary riboswitch binding results confirmed that 
structural variations of ligands are indeed accommo-
dated by the guanine riboswitch, indicative of avail-
able space in the riboswitch, and that both purine and 
pyrimidine scaffolds are tolerated in the binding site 
(Gilbert et al., 2006; Mulhbacher et al., 2010). This 
opens the way for finding analogs of PC1 that still bind 
to the Staph. aureus guanine riboswitch and that may 
be less subject to oxidative self-condensation.
CONCLUSIONS
Our data showed that PC1 can target Staph. aureus 
and Staph. epidermidis. Although stability, dosage, 
and formulation will need to be improved, PC1 can 
be safely administrated to dairy cows and can reduce 
Staph. aureus concentrations in experimentally infected 
quarters. The staphylococcal riboswitch is a valid drug 
Table 3. Effect of the intramammary infusion of saline or 2,5,6-triaminopyrimidine-4-one (PC1) for 7 d on 
SCC and quarter milk production for quarters experimentally infected with Staphylococcus aureus over the 
treatment and monitoring periods 
Infusion
SCC1 (log10/mL of milk) Quarter milk production
1 (kg)
Treatment Monitoring2 Treatment Monitoring2
Saline 6.20 ± 0.10 6.29 ± 0.11 3.69 ± 0.07 3.52 ± 0.12
PC1
 250 mg 6.03 ± 0.10 6.20 ± 0.11 3.72 ± 0.07 3.51 ± 0.12
 500 mg 6.17 ± 0.11 6.01 ± 0.12 3.66 ± 0.07 3.60 ± 0.12
1Data presented are LSM ± SEM. No statistical difference was observed for these parameters.
2Parameters were monitored for the 4 wk that followed the end of treatments.
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target and a continued exploration of therapeutic ap-
plications for PC1 and derivatives for the treatment of 
bovine mastitis have to be carried on.
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